Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00676143
Registration number
NCT00676143
Ethics application status
Date submitted
2/05/2008
Date registered
12/05/2008
Date last updated
10/06/2016
Titles & IDs
Public title
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
Query!
Scientific title
A Phase Iii, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy And Safety Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Mild To Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Carriers
Query!
Secondary ID [1]
0
0
B2521002
Query!
Secondary ID [2]
0
0
3133K1-3001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Alzheimer Disease
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Alzheimer's disease
Query!
Neurological
0
0
0
0
Query!
Dementias
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - bapineuzumab
Treatment: Drugs - placebo
Experimental: Bapineuzumab 0.5 mg/kg -
Placebo comparator: Placebo -
Treatment: Drugs: bapineuzumab
Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
Treatment: Drugs: placebo
Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)/11 Subscale Total Score at Week 78
Query!
Assessment method [1]
0
0
The ADAS-Cog is a multi-item, objective measure of cognitive function. The scale evaluates memory, language, and praxis with items such as orientation, word recall, word recognition, object identification, comprehension, and the completion of simple tasks. Analysis of the ADAS-Cog for this study was based upon an 11 item score from the following items 1) word recall task, 2) naming objects and fingers, 3) following commands, 4) constructional praxis, 5) ideational praxis, 6) orientation, 7) word recognition, 8) remembering test instructions, 9) spoken language ability, 10) word finding difficulty in spontaneous speech, and 11) comprehension.
This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced.
The ADAS-Cog/11 ranged from 0 to 70 points, with higher scores indicating a greater degree of impairment. A negative change from baseline indicates a decrease in cognitive impairment.
Query!
Timepoint [1]
0
0
Baseline and 78 weeks
Query!
Primary outcome [2]
0
0
Change From Baseline in Disability Assessment for Dementia (DAD) Total Score at Week 78
Query!
Assessment method [2]
0
0
The DAD measures instrumental and basic activities of daily living in participants with Alzheimer's Disease (AD). The DAD is administered to the participants'caregiver in the form of an interview. This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced by the participant.
This scale assesses a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item can be scored as 1 = yes, 0 = no, non applicable = NA. A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores indicate better function; a positive change from baseline indicates an improvement.
Query!
Timepoint [2]
0
0
Baseline and 78 weeks
Query!
Secondary outcome [1]
0
0
Change From Baseline in Brain Amyloid Burden at Week 71
Query!
Assessment method [1]
0
0
Brain amyloid burden as imaged by 11C-Pittsburgh compound B (PIB) positron emission tomography (PET). The latter is a semi-quantitative measure of the extent of fibrillar amyloid in the brain. PIB PET measurements were made in cortical regions found to have the highest burden of fibrillar amyloid at autopsy in participants diagnosed as having Alzheimer's pathology, and also regions reported to have the highest average retention of PIB signal in previous PET studies enrolling participants with probable AD. This parameter reflects overall brain amyloid deposition as indexed by imaging. The change from baseline was measured as average standard uptake value ratio (SUVr) in prespecified regions of interest (ROI) assessed by PIB PET imaging in a subset of participants.
Query!
Timepoint [1]
0
0
Baseline and 71 weeks
Query!
Secondary outcome [2]
0
0
Change From Baseline in Cerebrospinal Fluid (CSF) Phospho-tau Levels at Week 71
Query!
Assessment method [2]
0
0
Biomarkers CSF phospho-tau is an indicator of neuronal injury and neurodegeneration. An elevation in levels of tau, as well as specific p-tau species, is thought to be a marker for progressive cellular degeneration in AD. Accordingly, a reduction from baseline in levels of CSF tau in participants who received bapineuzumab compared with participants who received placebo may be indicative of a reduction in neuronal loss in participants treated with bapineuzumab.
Query!
Timepoint [2]
0
0
Baseline and 71 Weeks
Query!
Secondary outcome [3]
0
0
Change From Baseline in Brain Volume, as Assessed by Magnetic Resonance Imaging Brain Boundary Shift Integral (MRI BBSI), at Week 71
Query!
Assessment method [3]
0
0
Cerebral atrophy correlates closely with the gradual cognitive decline in AD and can be visualized by MRI. The BBSI technique involves positional matching of serial 3-dimensional MRI brain images, such that brain MRI-image volumes were first registered and then subtracted from each other. Atrophy rates would generally be expected to be lower if the underlying disease was attenuated by effective treatment.
Query!
Timepoint [3]
0
0
Baseline and 71 Weeks
Query!
Secondary outcome [4]
0
0
Divergence of Effect on the ADAS-Cog/11 Total Scores From Week 39 to Week 78
Query!
Assessment method [4]
0
0
Treatment differences are estimated using least-squares (LS) means with factor levels weighted according to overall analysis population proportions. ADAS-Cog/11 total score range is 0 (least impairment) to 70 (most impairment); a negative treatment difference (bapineuzumab minus placebo) favors bapineuzumab. Within the MMRMs for ADAS-Cog/11 described for the primary analyses, linear contrasts were formed to test increasing trend of the differences between bapineuzumab and placebo from Week 39 (the 9-month visit) through Week 78 (the 18 -month visit) for each variable, which is equivalent to testing a positive slope of the differences between each bapineuzumab dose group and placebo from Week 39 through Week 78. Results are from a restricted maximum likelihood (REML)-based mixed model for MMRM.
Query!
Timepoint [4]
0
0
Week 39 to Week 78
Query!
Secondary outcome [5]
0
0
Divergence of Effect on the DAD Total Scores From Week 39 to Week 78
Query!
Assessment method [5]
0
0
Treatment differences are estimated using least-squares (LS) means with factor levels weighted according to overall analysis population proportions. DAD total score range is 0 to 100; a positive treatment difference (bapineuzumab minus placebo) favors bapineuzumab. Within the MMRMs for ADAS-Cog/11 described for the primary analyses, linear contrasts were formed to test increasing trend of the differences between bapineuzumab and placebo from Week 39 (the 9-month visit) through Week 78 (the 18 -month visit) for each variable, which is equivalent to testing a positive slope of the differences between each bapineuzumab dose group and placebo from Week 39 through Week 78. Results are from a restricted maximum likelihood (REML)-based mixed model for MMRM.
Query!
Timepoint [5]
0
0
Week 39 to Week 78
Query!
Secondary outcome [6]
0
0
Time to First Median Placebo Deterioration on ADAS-Cog/11 Total Score (European Union [EU] Analysis Plan)
Query!
Assessment method [6]
0
0
The time to first median placebo deterioration, defined as the first time a participant experienced an increase (worsening) from baseline in ADAS-Cog/11 total score greater than or equal to the median worsening observed at Week 78 in the placebo group. The Kaplan Meier estimate of median time to first median placebo deterioration was presented.
Query!
Timepoint [6]
0
0
Baseline and 78 Weeks
Query!
Secondary outcome [7]
0
0
Time to First Clinically Meaningful Deterioration on ADAS-Cog/11 Total Score (United States [US] Analysis Plan)
Query!
Assessment method [7]
0
0
The time to first clinically meaningful deterioration was defined as the first time a participant experienced an increase (worsening) from baseline in ADAS-Cog/11 total score of \>=7.
Query!
Timepoint [7]
0
0
Baseline and 78 Weeks
Query!
Secondary outcome [8]
0
0
Time to First Median Placebo Deterioration on DAD Total Score (EU Analysis Plan)
Query!
Assessment method [8]
0
0
The time to first median placebo deterioration was defined as the first time a participant experienced a decrease (worsening) in DAD total score greater than or equal to the median worsening at Week 78 in the placebo group.
Query!
Timepoint [8]
0
0
Baseline and 78 Weeks
Query!
Secondary outcome [9]
0
0
Time to First Clinically Meaningful Deterioration on DAD Total Score (US Analysis)
Query!
Assessment method [9]
0
0
The time to first clinically meaningful deterioration was defined as the first time a participant experienced a decrease (worsening) from baseline in DAD total score of \>=12.
Query!
Timepoint [9]
0
0
Baseline and 78 Weeks
Query!
Secondary outcome [10]
0
0
Change From Baseline in Dependence Scale Total Score at Week 78
Query!
Assessment method [10]
0
0
The Dependence Scale (DS) is a 13-item, caregiver-rated instrument for determining the amount of support required by a participant with AD. The DS total score ranges from 0 to 15, with higher scores indicating more need for assistance. The DS was administered as an interview to the caregiver at scheduled study visits.
Query!
Timepoint [10]
0
0
Baseline and 78 Weeks
Query!
Secondary outcome [11]
0
0
Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (EU Analysis Plan)
Query!
Assessment method [11]
0
0
Percentage of participants with worsening from baseline to Week 78 in ADAS-Cog/11 total score of =0, =3, and =7 points were reported. In order to calculate time to first median placebo deterioration in ADAS-Cog/11, the median change from baseline to Week 78 among the placebo participants of the mITT analysis population were determined. The median changes were used as the cutpoints for determining "deterioration" for Alzheimer's disease participants in the study. If the median change from baseline to Week 78 in the ADAS-Cog/11 total score among the placebo participants of the mITT Analysis Population is 7 points, then the first median placebo deterioration is the first time where there is a worsening on the ADAS-Cog/11 total score of 7 points or more and the worsening is confirmed by the ADAS-Cog/11 assessment at the next non-missing visit.
Query!
Timepoint [11]
0
0
Baseline and 78 Weeks
Query!
Secondary outcome [12]
0
0
Percentage of Responders for ADAS-Cog/11 Total Score at Week 78 (US Analysis Plan)
Query!
Assessment method [12]
0
0
Percentage of participants whose increase (worsening) from baseline to Week 78 in ADAS-Cog/11 total score was \<7.
Query!
Timepoint [12]
0
0
Baseline and 78 Weeks
Query!
Secondary outcome [13]
0
0
Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (EU Analysis Plan)
Query!
Assessment method [13]
0
0
Percentage of participants whose decrease (worsening) from baseline to Week 78 in DAD total score of = 0, = 6, and = 12 points. In order to calculate time to first median placebo deterioration in DAD, the median change from baseline to Week 78 among the placebo participants of the mITT analysis population were determined. The median changes were used as the cutpoints for determining "deterioration" for Alzheimer's disease participants in the study. If the median change from baseline to Week 78 in the DAD total score among the placebo participants of the mITT Analysis Population is 7 points, then the first median placebo deterioration is the first time where there is a worsening on the DAD total score of 7 points or more and the worsening is confirmed by the DAD assessment at the next non-missing visit.
Query!
Timepoint [13]
0
0
Baseline and 78 Weeks
Query!
Secondary outcome [14]
0
0
Percentage of Responders for DAD Total Score at Week 78 (US Analysis Plan)
Query!
Assessment method [14]
0
0
Percentage of participants whose decrease (worsening) from baseline to Week 78 in DAD total score was \<12.
Query!
Timepoint [14]
0
0
Baseline and 78 Weeks
Query!
Secondary outcome [15]
0
0
Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB) Total Score at Week 78
Query!
Assessment method [15]
0
0
The CDR-SOB is a global clinical staging instrument that sums 6 clinical ratings: 1) memory, 2) orientation, 3) judgment and problem solving, 4) involvement in community affairs, 5) home and hobbies, and 6) personal care based on the Clinical Dementia Rating Scale (CDR) interview. The CDR includes discussions with the participant and caregiver using a structured format. This scale had to be administered by a trained and certified global rater who did not have access to any information regarding adverse events experienced by the participant. CDR-SOB total score range is 0 (least impairment) to 18 (most impairment); a negative change from baseline indicates an improvement.
Query!
Timepoint [15]
0
0
Baseline and 78 Weeks
Query!
Eligibility
Key inclusion criteria
* Diagnosis of probable AD, with MMSE score of 16-26, and brain MRI consistent with the diagnosis of AD
* Concurrent use of cholinesterase inhibitor or memantine allowed, if stable.
* Caregiver will participate and be able to attend clinic visits with patient.
Query!
Minimum age
50
Years
Query!
Query!
Maximum age
88
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Significant neurological disease other than AD, or a major psychiatric disorder
* Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body)
* Woman of childbearing potential
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/11/2012
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1100
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Gosford Hospital; Pharmacy Dept - Gosford
Query!
Recruitment hospital [2]
0
0
Gosford Hospital - Gosford
Query!
Recruitment hospital [3]
0
0
Hornsby Kuringai Hospital - Hornsby
Query!
Recruitment hospital [4]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [5]
0
0
The Queen Elizabeth Hospital - Woodville South
Query!
Recruitment hospital [6]
0
0
CDAMS Ballarat Base Hospital - Ballarat
Query!
Recruitment hospital [7]
0
0
Heidelberg Repatriation Hospital - West Heidelberg
Query!
Recruitment hospital [8]
0
0
Hollywood Hospital; Pharmacy Dept - Nedlands
Query!
Recruitment hospital [9]
0
0
McCusker Alzheimer's Research Foundation, Inc. - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2250 - Gosford
Query!
Recruitment postcode(s) [2]
0
0
2077 - Hornsby
Query!
Recruitment postcode(s) [3]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [4]
0
0
5011 - Woodville South
Query!
Recruitment postcode(s) [5]
0
0
3353 - Ballarat
Query!
Recruitment postcode(s) [6]
0
0
3081 - West Heidelberg
Query!
Recruitment postcode(s) [7]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kansas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Louisiana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Massachusetts
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Michigan
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Mississippi
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Missouri
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Jersey
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New York
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
North Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Ohio
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Oregon
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Pennsylvania
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Rhode Island
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
South Carolina
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Texas
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Vermont
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Wisconsin
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Buenos Aires
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Cordoba
Query!
Country [29]
0
0
Austria
Query!
State/province [29]
0
0
Graz
Query!
Country [30]
0
0
Austria
Query!
State/province [30]
0
0
Klagenfurt
Query!
Country [31]
0
0
Austria
Query!
State/province [31]
0
0
Wien
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Antwerpen
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Brugge
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Brussels
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Edegem
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Leuven
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Roeselare
Query!
Country [38]
0
0
Chile
Query!
State/province [38]
0
0
Santiago
Query!
Country [39]
0
0
Croatia
Query!
State/province [39]
0
0
Zagreb
Query!
Country [40]
0
0
Finland
Query!
State/province [40]
0
0
Kuopio
Query!
Country [41]
0
0
Finland
Query!
State/province [41]
0
0
Turku
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Bordeaux Cedex
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Bron
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Caen
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Colmar
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Dijon
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Lille
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Marseille
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Montpellier
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Nantes - Saint Herblain
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Nice
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Paris
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Poitiers
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Reims
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Rennes Cedex
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Rouen
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Toulouse
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Berlin
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Bochum
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Dresden
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Freiburg
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Offenburg
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Ulm
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Ancona
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Brescia
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Catania
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Chieti
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Milano
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Monza
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Roma
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Siena
Query!
Country [72]
0
0
Japan
Query!
State/province [72]
0
0
Aichi,
Query!
Country [73]
0
0
Japan
Query!
State/province [73]
0
0
Tokyo
Query!
Country [74]
0
0
Japan
Query!
State/province [74]
0
0
Aichi
Query!
Country [75]
0
0
Japan
Query!
State/province [75]
0
0
Chiba
Query!
Country [76]
0
0
Japan
Query!
State/province [76]
0
0
Fukuoka
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Gunma
Query!
Country [78]
0
0
Japan
Query!
State/province [78]
0
0
Hiroshima
Query!
Country [79]
0
0
Japan
Query!
State/province [79]
0
0
Hyogo
Query!
Country [80]
0
0
Japan
Query!
State/province [80]
0
0
Iwate
Query!
Country [81]
0
0
Japan
Query!
State/province [81]
0
0
Kagawa
Query!
Country [82]
0
0
Japan
Query!
State/province [82]
0
0
Kanagawa
Query!
Country [83]
0
0
Japan
Query!
State/province [83]
0
0
Kyoto
Query!
Country [84]
0
0
Japan
Query!
State/province [84]
0
0
Nagano
Query!
Country [85]
0
0
Japan
Query!
State/province [85]
0
0
Niigata
Query!
Country [86]
0
0
Japan
Query!
State/province [86]
0
0
Okayama
Query!
Country [87]
0
0
Japan
Query!
State/province [87]
0
0
Osaka
Query!
Country [88]
0
0
Japan
Query!
State/province [88]
0
0
Shizuoka
Query!
Country [89]
0
0
Mexico
Query!
State/province [89]
0
0
Nuevo León
Query!
Country [90]
0
0
Mexico
Query!
State/province [90]
0
0
Aguascalientes
Query!
Country [91]
0
0
Netherlands
Query!
State/province [91]
0
0
Noord Brabant
Query!
Country [92]
0
0
Netherlands
Query!
State/province [92]
0
0
Noord Holland
Query!
Country [93]
0
0
Netherlands
Query!
State/province [93]
0
0
The Netherlands
Query!
Country [94]
0
0
Netherlands
Query!
State/province [94]
0
0
's-Hertogenbosch
Query!
Country [95]
0
0
Netherlands
Query!
State/province [95]
0
0
Alkmaar
Query!
Country [96]
0
0
Netherlands
Query!
State/province [96]
0
0
Amsterdam
Query!
Country [97]
0
0
Netherlands
Query!
State/province [97]
0
0
Eindhoven
Query!
Country [98]
0
0
Netherlands
Query!
State/province [98]
0
0
Leeuwarden
Query!
Country [99]
0
0
Netherlands
Query!
State/province [99]
0
0
Rotterdam
Query!
Country [100]
0
0
New Zealand
Query!
State/province [100]
0
0
NZ
Query!
Country [101]
0
0
New Zealand
Query!
State/province [101]
0
0
Christchurch
Query!
Country [102]
0
0
Poland
Query!
State/province [102]
0
0
Bydgoszcz
Query!
Country [103]
0
0
Poland
Query!
State/province [103]
0
0
Krakow
Query!
Country [104]
0
0
Poland
Query!
State/province [104]
0
0
Poznan
Query!
Country [105]
0
0
Poland
Query!
State/province [105]
0
0
Warszawa
Query!
Country [106]
0
0
Portugal
Query!
State/province [106]
0
0
Amadora
Query!
Country [107]
0
0
Portugal
Query!
State/province [107]
0
0
Coimbra
Query!
Country [108]
0
0
Portugal
Query!
State/province [108]
0
0
Lisboa
Query!
Country [109]
0
0
Serbia
Query!
State/province [109]
0
0
Belgrade
Query!
Country [110]
0
0
Serbia
Query!
State/province [110]
0
0
Kragujevac
Query!
Country [111]
0
0
Serbia
Query!
State/province [111]
0
0
Novi Sad
Query!
Country [112]
0
0
Serbia
Query!
State/province [112]
0
0
Sremska Kamenica
Query!
Country [113]
0
0
Slovakia
Query!
State/province [113]
0
0
Bratislava
Query!
Country [114]
0
0
Slovakia
Query!
State/province [114]
0
0
Michalovce
Query!
Country [115]
0
0
Slovakia
Query!
State/province [115]
0
0
Rimavska Sobota
Query!
Country [116]
0
0
South Africa
Query!
State/province [116]
0
0
Gauteng
Query!
Country [117]
0
0
South Africa
Query!
State/province [117]
0
0
Kwa Zulu Natal
Query!
Country [118]
0
0
South Africa
Query!
State/province [118]
0
0
Western Cape
Query!
Country [119]
0
0
Spain
Query!
State/province [119]
0
0
Alicante
Query!
Country [120]
0
0
Spain
Query!
State/province [120]
0
0
Barcelona
Query!
Country [121]
0
0
Spain
Query!
State/province [121]
0
0
Caceres
Query!
Country [122]
0
0
Spain
Query!
State/province [122]
0
0
Islas Baleares
Query!
Country [123]
0
0
Spain
Query!
State/province [123]
0
0
Pais Vasco
Query!
Country [124]
0
0
Spain
Query!
State/province [124]
0
0
Vizcalla
Query!
Country [125]
0
0
Spain
Query!
State/province [125]
0
0
Burgos
Query!
Country [126]
0
0
Spain
Query!
State/province [126]
0
0
Madrid
Query!
Country [127]
0
0
Spain
Query!
State/province [127]
0
0
Murcia
Query!
Country [128]
0
0
Sweden
Query!
State/province [128]
0
0
Malmo
Query!
Country [129]
0
0
Sweden
Query!
State/province [129]
0
0
Uppsala
Query!
Country [130]
0
0
Switzerland
Query!
State/province [130]
0
0
BS
Query!
Country [131]
0
0
Switzerland
Query!
State/province [131]
0
0
GE
Query!
Country [132]
0
0
Switzerland
Query!
State/province [132]
0
0
VD
Query!
Country [133]
0
0
Switzerland
Query!
State/province [133]
0
0
Thonex-Geneva
Query!
Country [134]
0
0
United Kingdom
Query!
State/province [134]
0
0
Lancashire
Query!
Country [135]
0
0
United Kingdom
Query!
State/province [135]
0
0
Manchester
Query!
Country [136]
0
0
United Kingdom
Query!
State/province [136]
0
0
Bradford
Query!
Country [137]
0
0
United Kingdom
Query!
State/province [137]
0
0
Brighton
Query!
Country [138]
0
0
United Kingdom
Query!
State/province [138]
0
0
Glasgow
Query!
Country [139]
0
0
United Kingdom
Query!
State/province [139]
0
0
London
Query!
Country [140]
0
0
United Kingdom
Query!
State/province [140]
0
0
Newcastle upon Tyne
Query!
Country [141]
0
0
United Kingdom
Query!
State/province [141]
0
0
Northampton
Query!
Country [142]
0
0
United Kingdom
Query!
State/province [142]
0
0
Penarth
Query!
Country [143]
0
0
United Kingdom
Query!
State/province [143]
0
0
Sheffield
Query!
Country [144]
0
0
United Kingdom
Query!
State/province [144]
0
0
Swindon
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00676143
Query!
Trial related presentations / publications
Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, Lobello K, Li D, McRae T, Lucas P, Evans I, Booth K, Luscan G, Wyman BT, Hua L, Yang L, Brashear HR, Black RS; Bapineuzumab 3000 and 3001 Clinical Study Investigators. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016 May 12;8(1):18. doi: 10.1186/s13195-016-0189-7. Lacey L, Bobula J, Rudell K, Alvir J, Leibman C. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed. Value Health. 2015 Jul;18(5):638-45. doi: 10.1016/j.jval.2015.03.1787. Epub 2015 Apr 10.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00676143
Download to PDF